Highlights

array(40) {
  [0]=>
  string(4) "1930"
  ["article_id"]=>
  string(4) "1930"
  [1]=>
  string(65) "FDA Approves Dovato (dolutegravir/lamivudine) for HIV-1 Infection"
  ["article_title"]=>
  string(65) "FDA Approves Dovato (dolutegravir/lamivudine) for HIV-1 Infection"
  [2]=>
  string(150) "LONDON--(BUSINESS WIRE) April 08, 2019 --ViiV Healthcare today announced that the US Food and Drug Administration (FDA) approved Dovato, a complete, o"
  ["short_description"]=>
  string(150) "LONDON--(BUSINESS WIRE) April 08, 2019 --ViiV Healthcare today announced that the US Food and Drug Administration (FDA) approved Dovato, a complete, o"
  [3]=>
  string(249) "LONDON--(BUSINESS WIRE) April 08, 2019 --ViiV Healthcare today announced that the US Food and Drug Administration (FDA) approved Dovato, a complete, once-daily, single-tablet regimen of dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg for the..."
  ["description"]=>
  string(249) "LONDON--(BUSINESS WIRE) April 08, 2019 --ViiV Healthcare today announced that the US Food and Drug Administration (FDA) approved Dovato, a complete, once-daily, single-tablet regimen of dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg for the..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(215) "https://www.drugs.com/newdrugs/fda-approves-dovato-dolutegravir-lamivudine-hiv-1-infection-4944.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Dovato+%28dolutegravir%2Flamivudine%29+for+HIV-1+Infection"
  ["blog_url"]=>
  string(215) "https://www.drugs.com/newdrugs/fda-approves-dovato-dolutegravir-lamivudine-hiv-1-infection-4944.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Dovato+%28dolutegravir%2Flamivudine%29+for+HIV-1+Infection"
  [15]=>
  string(19) "2019-04-09 07:04:46"
  ["add_date"]=>
  string(19) "2019-04-09 07:04:46"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:51"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:51"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

FDA Approves Dovato (dolutegravir/lamivudine) for HIV-1 Infection

LONDON--(BUSINESS WIRE) April 08, 2019 --ViiV Healthcare today announced that the US Food and Drug Administration (FDA)

array(40) {
  [0]=>
  string(4) "1820"
  ["article_id"]=>
  string(4) "1820"
  [1]=>
  string(52) "Using Agile Values for Medical Device Development"
  ["article_title"]=>
  string(52) "Using Agile Values for Medical Device Development"
  [2]=>
  string(158) "Although designed for software, Agile’s fundamental values are equally relevant to medical devices.&#nlThe post Using Agile Values for Medical Device&n"
  ["short_description"]=>
  string(158) "Although designed for software, Agile’s fundamental values are equally relevant to medical devices.&#nlThe post Using Agile Values for Medical Device&n"
  [3]=>
  string(451) "

Although designed for software, Agile’s fundamental values are equally relevant to medical devices.

&#nl

The post Using Agile Values for Medical Device Development appeared first on MedTech Intelligence.

&#nl" ["description"]=> string(451) "

Although designed for software, Agile’s fundamental values are equally relevant to medical devices.

&#nl

The post Using Agile Values for Medical Device Development appeared first on MedTech Intelligence.

&#nl" [4]=> NULL ["image"]=> NULL [5]=> NULL ["big_image"]=> NULL [6]=> NULL ["feature_images"]=> NULL [7]=> NULL ["employer_id"]=> NULL [8]=> string(1) "1" ["category"]=> string(1) "1" [9]=> string(3) "RSS" ["added_by"]=> string(3) "RSS" [10]=> string(2) "10" ["status"]=> string(2) "10" [11]=> NULL ["highlight_status"]=> NULL [12]=> NULL ["hit_count"]=> NULL [13]=> string(2) "98" ["rss_id"]=> string(2) "98" [14]=> string(93) "https://www.medtechintelligence.com/column/using-agile-values-for-medical-device-development/" ["blog_url"]=> string(93) "https://www.medtechintelligence.com/column/using-agile-values-for-medical-device-development/" [15]=> string(19) "2019-04-08 19:30:20" ["add_date"]=> string(19) "2019-04-08 19:30:20" [16]=> NULL ["bythe"]=> NULL [17]=> NULL ["timestamp"]=> NULL [18]=> string(19) "2019-04-15 14:56:01" ["create_at"]=> string(19) "2019-04-15 14:56:01" [19]=> string(0) "" ["slug"]=> string(0) "" }

Using Agile Values for Medical Device Development

Although designed for software, Agile’s fundamental values are equally relevant to medical devices.

&#nl

array(40) {
  [0]=>
  string(4) "1937"
  ["article_id"]=>
  string(4) "1937"
  [1]=>
  string(112) "Zogenix Receives Refusal to File Letter from U.S. Food and Drug Administration for Fintepla New Drug Application"
  ["article_title"]=>
  string(112) "Zogenix Receives Refusal to File Letter from U.S. Food and Drug Administration for Fintepla New Drug Application"
  [2]=>
  string(150) "EMERYVILLE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies"
  ["short_description"]=>
  string(150) "EMERYVILLE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies"
  [3]=>
  string(246) "EMERYVILLE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug..."
  ["description"]=>
  string(246) "EMERYVILLE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(202) "https://www.drugs.com/nda/fintepla_190408.html?utm_source=ddc&utm_medium=rss&utm_campaign=Zogenix+Receives+Refusal+to+File+Letter+from+U.S.+Food+and+Drug+Administration+for+Fintepla+New+Drug+Application"
  ["blog_url"]=>
  string(202) "https://www.drugs.com/nda/fintepla_190408.html?utm_source=ddc&utm_medium=rss&utm_campaign=Zogenix+Receives+Refusal+to+File+Letter+from+U.S.+Food+and+Drug+Administration+for+Fintepla+New+Drug+Application"
  [15]=>
  string(19) "2019-04-08 15:04:54"
  ["add_date"]=>
  string(19) "2019-04-08 15:04:54"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:51"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:51"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

Zogenix Receives Refusal to File Letter from U.S. Food and Drug Administration for Fintepl

EMERYVILLE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company dev

array(40) {
  [0]=>
  string(4) "4862"
  ["article_id"]=>
  string(4) "4862"
  [1]=>
  string(68) "Targeted Protein Degradation Summit, October 22-24 2019, Boston, USA"
  ["article_title"]=>
  string(68) "Targeted Protein Degradation Summit, October 22-24 2019, Boston, USA"
  [2]=>
  string(150) "The 2nd TPD 2019 is a specifically dedicated scientific and networking forum for large pharma, innovative biotech and research institutes to capitaliz"
  ["short_description"]=>
  string(150) "The 2nd TPD 2019 is a specifically dedicated scientific and networking forum for large pharma, innovative biotech and research institutes to capitaliz"
  [3]=>
  string(515) "The 2nd TPD 2019 is a specifically dedicated scientific and networking forum for large pharma, innovative biotech and research institutes to capitalize on the emerging therapeutic class of protein degradation.&#nlAs the drug discovery opportunity promised within the proteome becomes a reality and previously "undruggable" targets are reached, the 2nd TPD Summit returns for 2019.&#nlThis premier event exists not only to drive forward the translation of first generation of PROTACS and molecular glues..."
  ["description"]=>
  string(515) "The 2nd TPD 2019 is a specifically dedicated scientific and networking forum for large pharma, innovative biotech and research institutes to capitalize on the emerging therapeutic class of protein degradation.&#nlAs the drug discovery opportunity promised within the proteome becomes a reality and previously "undruggable" targets are reached, the 2nd TPD Summit returns for 2019.&#nlThis premier event exists not only to drive forward the translation of first generation of PROTACS and molecular glues..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(97) "https://www.pharmiweb.com/event/targeted-protein-degradation-summit-october-22-24-2019-boston-usa"
  ["blog_url"]=>
  string(97) "https://www.pharmiweb.com/event/targeted-protein-degradation-summit-october-22-24-2019-boston-usa"
  [15]=>
  string(19) "2019-04-06 14:52:43"
  ["add_date"]=>
  string(19) "2019-04-06 14:52:43"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-27 14:12:08"
  ["create_at"]=>
  string(19) "2019-09-27 14:12:08"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

Targeted Protein Degradation Summit, October 22-24 2019, Boston, USA

The 2nd TPD 2019 is a specifically dedicated scientific and networking forum for large pharma, innovative biotech and re

array(40) {
  [0]=>
  string(4) "2032"
  ["article_id"]=>
  string(4) "2032"
  [1]=>
  string(67) "Australia Proposes New Device Classifications to Align With EU Regs"
  ["article_title"]=>
  string(67) "Australia Proposes New Device Classifications to Align With EU Regs"
  [2]=>
  string(158) "&#nl        Australia’s TGA released five new draft guidances that propose changes to the classification of numerous medical devices to align more clos"
  ["short_description"]=>
  string(158) "&#nl        Australia’s TGA released five new draft guidances that propose changes to the classification of numerous medical devices to align more clos"
  [3]=>
  string(204) "&#nl        Australia’s TGA released five new draft guidances that propose changes to the classification of numerous medical devices to align more closely with European Union regulations.&#nl      "
  ["description"]=>
  string(204) "&#nl        Australia’s TGA released five new draft guidances that propose changes to the classification of numerous medical devices to align more closely with European Union regulations.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "19"
  ["rss_id"]=>
  string(2) "19"
  [14]=>
  string(107) "https://www.fdanews.com/articles/190842-australia-proposes-new-device-classifications-to-align-with-eu-regs"
  ["blog_url"]=>
  string(107) "https://www.fdanews.com/articles/190842-australia-proposes-new-device-classifications-to-align-with-eu-regs"
  [15]=>
  string(19) "2019-04-06 00:07:25"
  ["add_date"]=>
  string(19) "2019-04-06 00:07:25"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:59"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:59"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

Australia Proposes New Device Classifications to Align With EU Regs

&#nl Australia’s TGA released five new draft guidances that propose changes to the classification of numer

array(40) {
  [0]=>
  string(4) "2033"
  ["article_id"]=>
  string(4) "2033"
  [1]=>
  string(71) "CDRH Warns of Device Shortages Following Sterilizer’s Suspension"
  ["article_title"]=>
  string(71) "CDRH Warns of Device Shortages Following Sterilizer’s Suspension"
  [2]=>
  string(153) "&#nl        CDRH warned that more than 100 device manufacturers and hundreds of devices face potential shortages following an EPA order to stop medical e"
  ["short_description"]=>
  string(153) "&#nl        CDRH warned that more than 100 device manufacturers and hundreds of devices face potential shortages following an EPA order to stop medical e"
  [3]=>
  string(278) "&#nl        CDRH warned that more than 100 device manufacturers and hundreds of devices face potential shortages following an EPA order to stop medical equipment sterilizer Sterigenics’ Willbrook, Illinois facility from sterilizing products with ethylene oxide.&#nl      "
  ["description"]=>
  string(278) "&#nl        CDRH warned that more than 100 device manufacturers and hundreds of devices face potential shortages following an EPA order to stop medical equipment sterilizer Sterigenics’ Willbrook, Illinois facility from sterilizing products with ethylene oxide.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "19"
  ["rss_id"]=>
  string(2) "19"
  [14]=>
  string(103) "https://www.fdanews.com/articles/190841-cdrh-warns-of-device-shortages-following-sterilizers-suspension"
  ["blog_url"]=>
  string(103) "https://www.fdanews.com/articles/190841-cdrh-warns-of-device-shortages-following-sterilizers-suspension"
  [15]=>
  string(19) "2019-04-06 00:06:13"
  ["add_date"]=>
  string(19) "2019-04-06 00:06:13"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:59"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:59"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

CDRH Warns of Device Shortages Following Sterilizer’s Suspension

&#nl CDRH warned that more than 100 device manufacturers and hundreds of devices face potential shortages followi

array(40) {
  [0]=>
  string(4) "2034"
  ["article_id"]=>
  string(4) "2034"
  [1]=>
  string(50) "EC Issues Guidance on Eudamed, Nomenclature System"
  ["article_title"]=>
  string(50) "EC Issues Guidance on Eudamed, Nomenclature System"
  [2]=>
  string(153) "&#nl        The European Commission released long-awaited guidance on Eudamed (the European Database on Medical Devices) and the device nomenclature syst"
  ["short_description"]=>
  string(153) "&#nl        The European Commission released long-awaited guidance on Eudamed (the European Database on Medical Devices) and the device nomenclature syst"
  [3]=>
  string(259) "&#nl        The European Commission released long-awaited guidance on Eudamed (the European Database on Medical Devices) and the device nomenclature system that will be used for the EU’s new medical device and in vitro diagnostic regulations.&#nl      "
  ["description"]=>
  string(259) "&#nl        The European Commission released long-awaited guidance on Eudamed (the European Database on Medical Devices) and the device nomenclature system that will be used for the EU’s new medical device and in vitro diagnostic regulations.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "19"
  ["rss_id"]=>
  string(2) "19"
  [14]=>
  string(89) "https://www.fdanews.com/articles/190840-ec-issues-guidance-on-eudamed-nomenclature-system"
  ["blog_url"]=>
  string(89) "https://www.fdanews.com/articles/190840-ec-issues-guidance-on-eudamed-nomenclature-system"
  [15]=>
  string(19) "2019-04-06 00:05:15"
  ["add_date"]=>
  string(19) "2019-04-06 00:05:15"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:59"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:59"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

EC Issues Guidance on Eudamed, Nomenclature System

&#nl The European Commission released long-awaited guidance on Eudamed (the European Database on Medical Devices)

array(40) {
  [0]=>
  string(4) "2035"
  ["article_id"]=>
  string(4) "2035"
  [1]=>
  string(67) "MITA Urges FDA to Clarify Servicing And Remanufacturing Differences"
  ["article_title"]=>
  string(67) "MITA Urges FDA to Clarify Servicing And Remanufacturing Differences"
  [2]=>
  string(153) "&#nl        The Medical Imaging & Technology Alliance is calling on the FDA to establish a framework that distinguishes between servicing and remanufactu"
  ["short_description"]=>
  string(153) "&#nl        The Medical Imaging & Technology Alliance is calling on the FDA to establish a framework that distinguishes between servicing and remanufactu"
  [3]=>
  string(207) "&#nl        The Medical Imaging & Technology Alliance is calling on the FDA to establish a framework that distinguishes between servicing and remanufacturing activities for medical imaging devices.&#nl      "
  ["description"]=>
  string(207) "&#nl        The Medical Imaging & Technology Alliance is calling on the FDA to establish a framework that distinguishes between servicing and remanufacturing activities for medical imaging devices.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "19"
  ["rss_id"]=>
  string(2) "19"
  [14]=>
  string(107) "https://www.fdanews.com/articles/190838-mita-urges-fda-to-clarify-servicing-and-remanufacturing-differences"
  ["blog_url"]=>
  string(107) "https://www.fdanews.com/articles/190838-mita-urges-fda-to-clarify-servicing-and-remanufacturing-differences"
  [15]=>
  string(19) "2019-04-06 00:03:22"
  ["add_date"]=>
  string(19) "2019-04-06 00:03:22"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:59"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:59"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

MITA Urges FDA to Clarify Servicing And Remanufacturing Differences

&#nl The Medical Imaging & Technology Alliance is calling on the FDA to establish a framework that distinguishes

array(40) {
  [0]=>
  string(4) "1809"
  ["article_id"]=>
  string(4) "1809"
  [1]=>
  string(56) "Categories refined for the 2019 PharmaTimes Sales Awards"
  ["article_title"]=>
  string(56) "Categories refined for the 2019 PharmaTimes Sales Awards"
  [2]=>
  string(148) "The categories for the 2019 PharmaTimes Sales Awards have been refined to greater reflect current trends and changes in the healthcare sales sector."
  ["short_description"]=>
  string(148) "The categories for the 2019 PharmaTimes Sales Awards have been refined to greater reflect current trends and changes in the healthcare sales sector."
  [3]=>
  string(148) "The categories for the 2019 PharmaTimes Sales Awards have been refined to greater reflect current trends and changes in the healthcare sales sector."
  ["description"]=>
  string(148) "The categories for the 2019 PharmaTimes Sales Awards have been refined to greater reflect current trends and changes in the healthcare sales sector."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(96) "http://www.pharmatimes.com/news/categories_refined_for_the_2019_pharmatimes_sales_awards_1283582"
  ["blog_url"]=>
  string(96) "http://www.pharmatimes.com/news/categories_refined_for_the_2019_pharmatimes_sales_awards_1283582"
  [15]=>
  string(19) "2019-04-05 21:07:37"
  ["add_date"]=>
  string(19) "2019-04-05 21:07:37"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-04-08 15:10:57"
  ["create_at"]=>
  string(19) "2019-04-08 15:10:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

Categories refined for the 2019 PharmaTimes Sales Awards

The categories for the 2019 PharmaTimes Sales Awards have been refined to greater reflect current trends and changes in

array(40) {
  [0]=>
  string(4) "1975"
  ["article_id"]=>
  string(4) "1975"
  [1]=>
  string(57) "Diagnosis and management of idiopathic pulmonary fibrosis"
  ["article_title"]=>
  string(57) "Diagnosis and management of idiopathic pulmonary fibrosis"
  [2]=>
  string(150) "Pharmacists can play a vital role in the diagnosis and management of idiopathic pulmonary fibrosis, and can help improve outcomes and the burden of di"
  ["short_description"]=>
  string(150) "Pharmacists can play a vital role in the diagnosis and management of idiopathic pulmonary fibrosis, and can help improve outcomes and the burden of di"
  [3]=>
  string(156) "Pharmacists can play a vital role in the diagnosis and management of idiopathic pulmonary fibrosis, and can help improve outcomes and the burden of disease."
  ["description"]=>
  string(156) "Pharmacists can play a vital role in the diagnosis and management of idiopathic pulmonary fibrosis, and can help improve outcomes and the burden of disease."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "12"
  ["rss_id"]=>
  string(2) "12"
  [14]=>
  string(134) "https://www.pharmaceutical-journal.com/learning/cpd-article/diagnosis-and-management-of-idiopathic-pulmonary-fibrosis/20206233.article"
  ["blog_url"]=>
  string(134) "https://www.pharmaceutical-journal.com/learning/cpd-article/diagnosis-and-management-of-idiopathic-pulmonary-fibrosis/20206233.article"
  [15]=>
  string(19) "2019-04-05 20:37:00"
  ["add_date"]=>
  string(19) "2019-04-05 20:37:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:55"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:55"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

Diagnosis and management of idiopathic pulmonary fibrosis

Pharmacists can play a vital role in the diagnosis and management of idiopathic pulmonary fibrosis, and can help improve

array(40) {
  [0]=>
  string(4) "1810"
  ["article_id"]=>
  string(4) "1810"
  [1]=>
  string(56) "AZ's Fasenra shows promise in hypereosinophilic syndrome"
  ["article_title"]=>
  string(56) "AZ's Fasenra shows promise in hypereosinophilic syndrome"
  [2]=>
  string(59) "The drug is AstraZeneca’s first respiratory biologic."
  ["short_description"]=>
  string(59) "The drug is AstraZeneca’s first respiratory biologic."
  [3]=>
  string(59) "The drug is AstraZeneca’s first respiratory biologic."
  ["description"]=>
  string(59) "The drug is AstraZeneca’s first respiratory biologic."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(95) "http://www.pharmatimes.com/news/azs_fasenra_shows_promise_in_hypereosinophilic_syndrome_1283678"
  ["blog_url"]=>
  string(95) "http://www.pharmatimes.com/news/azs_fasenra_shows_promise_in_hypereosinophilic_syndrome_1283678"
  [15]=>
  string(19) "2019-04-05 18:45:51"
  ["add_date"]=>
  string(19) "2019-04-05 18:45:51"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-04-08 15:10:57"
  ["create_at"]=>
  string(19) "2019-04-08 15:10:57"
  [19]=>
  string(56) "AZ_s_Fasenra_shows_promise_in_hypereosinophilic_syndrome"
  ["slug"]=>
  string(56) "AZ_s_Fasenra_shows_promise_in_hypereosinophilic_syndrome"
}
                    

AZ's Fasenra shows promise in hypereosinophilic syndrome

The drug is AstraZeneca’s first respiratory biologic.

array(40) {
  [0]=>
  string(4) "1811"
  ["article_id"]=>
  string(4) "1811"
  [1]=>
  string(48) "Myriad, AstraZeneca and MSD expand collaboration"
  ["article_title"]=>
  string(48) "Myriad, AstraZeneca and MSD expand collaboration"
  [2]=>
  string(76) "The expansion will use BRACAnalysis CDx to identify germline BRCA mutations."
  ["short_description"]=>
  string(76) "The expansion will use BRACAnalysis CDx to identify germline BRCA mutations."
  [3]=>
  string(76) "The expansion will use BRACAnalysis CDx to identify germline BRCA mutations."
  ["description"]=>
  string(76) "The expansion will use BRACAnalysis CDx to identify germline BRCA mutations."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(88) "http://www.pharmatimes.com/news/myriad,_astrazeneca_and_msd_expand_collaboration_1283621"
  ["blog_url"]=>
  string(88) "http://www.pharmatimes.com/news/myriad,_astrazeneca_and_msd_expand_collaboration_1283621"
  [15]=>
  string(19) "2019-04-05 16:46:57"
  ["add_date"]=>
  string(19) "2019-04-05 16:46:57"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-04-08 15:10:57"
  ["create_at"]=>
  string(19) "2019-04-08 15:10:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

Myriad, AstraZeneca and MSD expand collaboration

The expansion will use BRACAnalysis CDx to identify germline BRCA mutations.